Engineered bacteria offer a promising alternative to antibiotics in addressing the menace of poultry necrotic enteritis, a disease causing substantial economic losses amounting to an estimated $6 billion annually. This innovative approach involves the utilization of a specially designed probiotic that could potentially revolutionize the poultry industry’s approach to combating necrotic enteritis.
Necrotic enteritis poses a significant threat to broiler chickens, often arising as a complication of other underlying diseases such as coccidiosis or conditions leading to immunosuppression. The disease is triggered byClostridium perfringens, a bacterium that thrives in the intestines due to existing damage, producing harmful toxins that contribute to mortality rates among affected birds.
The engineered probiotic at the forefront of this groundbreaking solution employs genetically modified lactobacillus strains capable of generating neutralizing antibodies against the toxins produced byC. perfringens. Unlike conventional antibiotics that indiscriminately eradicate bacteria and may foster resistance, this probiotic selectively targets the disease-causing toxins while preserving beneficial commensal bacteria critical for gut health.
BiomEdit, under the leadership of CEO Aaron Schacht, identified necrotic enteritis as a key challenge necessitating a paradigm shift away from reliance on antibiotics. By strategically leveraging engineered probiotics, the company aims to provide a sustainable and effective alternative to combatting this debilitating poultry disease.
The development journey of this engineered probiotic involved extracting toxoids fromC. perfringens, leveraging llamas to produce single-chain antibodies, and subsequently integrating these nanobody genes into carefully selected lactobacillus strains. This meticulous process resulted in the creation of two synergistic bacterial strains, each armed with antibodies targeting specific toxins associated with necrotic enteritis.
Administration of the probiotic involves a day-of-hatch spray application, allowing the birds to naturally ingest the beneficial bacteria through their regular pecking behavior. A supplementary booster dose provided via drinking water around day 14 ensures sustained levels of the probiotic colonies throughout the critical period of a typical 43-day growth cycle, effectively safeguarding against necrotic enteritis occurrence.
The engineered probiotic has advanced to the final phase of the U.S. Department of Agriculture’s (USDA) conditional licensure process, signifying a significant milestone in its journey towards regulatory approval and eventual market availability. The company’s successful closure of a Series B funding round, securing approximately $18.4 million in investments led by Anterra Capital, underscores the industry’s confidence in this innovative solution despite prevailing market challenges.
Looking ahead, BiomEdit aims to steer towards commercialization and anticipates market entry by November 2026, aligning with its mission to deliver a sustainable and impactful alternative to antibiotics in poultry farming. This strategic roadmap underscores the company’s commitment to addressing critical industry challenges and revolutionizing poultry health management practices.
Key Takeaways:
- Engineered probiotics offer a promising alternative to antibiotics in combating poultry necrotic enteritis, a disease causing significant economic losses in the poultry industry.
- The probiotic solution utilizes genetically modified lactobacillus strains to produce neutralizing antibodies against toxins fromClostridium perfringens, targeting the root cause of necrotic enteritis.
- BiomEdit’s innovative approach has garnered substantial support, positioning the engineered probiotic for regulatory approval and eventual market entry by 2026.
In conclusion, the advent of engineered probiotics heralds a new era in poultry health management, providing a sustainable and effective alternative to antibiotics in addressing necrotic enteritis. By harnessing cutting-edge biotechnology, BiomEdit’s pioneering solution exemplifies the industry’s commitment to innovation and sustainable practices, offering a beacon of hope for a future where poultry diseases can be effectively mitigated without reliance on traditional antibiotics.
Tags: formulation
Read more on wattagnet.com